LiPlasome is a Danish privately owned biotech company focusing on oncology.

The LiPlasome technology provides a liplasomal reformulation of the most used anticancer drugs on the market like Cispaltin -> LiPlaCis®, Oxaliplatin -> LiPloxa.

The aim is to provide more effective treatment to cancer patients with fewer side effects.

LiPlasomes most advanced program I LiPlaCis® in a close escalating clinical phase I trial. In addition two programs are in pre-clinical development.